Form 4: Moderna Director Sandra Horning Exercises RSU Award

Moderna, Inc. Director Sandra Horning acquired 16,233 shares of common stock following the vesting of restricted stock units.

Summary

• Director Sandra Horning acquired 16,233 shares of Moderna, Inc. (MRNA) common stock.
• The acquisition resulted from the vesting of restricted stock units (RSUs) on April 30, 2026.
• The RSUs converted into common stock on a one-for-one basis at no additional cost.
• Following this transaction, the reporting person holds a total of 18,585 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine equity compensation.

Positives

• The transaction reflects the fulfillment of equity-based compensation, aligning director interests with long-term shareholder value.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of equity compensation vesting for a corporate director, which is standard practice in the biotechnology sector to maintain transparency regarding insider holdings.

Comparison to Industry Standards

• The transaction follows standard corporate governance practices for equity-based compensation vesting.
• The reporting of RSU conversion is consistent with SEC requirements for publicly traded companies like Pfizer, Merck, and BioNTech.

Stakeholder Impact

• Minimal impact on shareholders as this represents standard equity compensation vesting.

Next Steps

• None mentioned.

Key Dates

Keywords

Moderna, MRNA, Form 4, Insider Trading, Equity Compensation, Sandra Horning